Pacira BioSciences (PCRX)
(Delayed Data from NSDQ)
$14.54 USD
+0.21 (1.47%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $14.54 0.00 (0.00%) 6:54 PM ET
3-Hold of 5 3
A Value B Growth F Momentum A VGM
Price, Consensus and EPS Surprise
PCRX 14.54 +0.21(1.47%)
Will PCRX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for PCRX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for PCRX
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
PCRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Pacira (PCRX) Down 27.9% Since Last Earnings Report: Can It Rebound?
Pacira (PCRX) Plummets as US Court Deems Exparel Patent Invalid
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
Other News for PCRX
Pacira BioSciences appoints Lauren Riker as interim CFO
Pacira Announces the Presentation of 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee
Pacira presents 104-week safety, efficacy data following PCRX-201 administration
PharmaCorp Announces Agreement to Acquire a Pharmacy in Atlantic Canada
DOMA Perpetual Sends Letter to Board of Directors of Pacira Biosciences to Immediately Accelerate and Increase its Share Buyback Program to Enhance Return to Shareholders